ERBB2 and gastric cancer: In a retrospective study of 158 patients with advanced gastric cancer treated with dual PD-1 and HER2 blockade, a higher SATI level was found to be an independent protective factor for progression-free survival (HR, 0.628, 95% CI: 0.410-0.962, P = 0.032) and was associated with a better treatment response than a lower SATI level (62.6% vs. 34.3%, P = 0.004)28.